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Hsp60 in eukaryotes is considered typically a mitochondrial 
chaperone (also called Cpn60) but in the last few years it has 
become clear that it also occurs in the cytosol, the cell surface, 
the extracellular space and in the peripheral blood. Studies with 
prokaryotic models have shown that Hsp60 plays a role in assisting 
nascent polypeptides to reach a native conformation, and that it 
interacts with Hsp10 (which also resides in the mitochondria and is 
also named Cpn10). In addition to its role in polypeptide folding in 
association with Hsp10, other functions and interacting molecules 
have been identified for Hsp60 in the last several years. Some of 
these newly identified functions are associated with carcinogen-
esis, specifically with tumor cell survival and proliferation. Thus, 
assessing the levels of Hsp60 in tumor cells and in sera of cancer 
patients is becoming an attractive area of investigation aiming at 
the development of means for practical applications in clinical 
oncology. Since Hsp60 participates in extracellular molecular inter-
actions and cell signalling and also in key intracellular pathways of 
some types of tumor cells, the idea of using Hsp60 in anti-cancer 
therapy (chaperonotherapy) is being investigated. The Hsp could 
be used either as an anticancer agent alone or in combination with 
tumor antigens, or as target for anti-chaperone compounds. In this 
article, a brief review is presented of representative research efforts 
aimed at assessing Hsp60 in a variety of tumors with the purpose of 
illustrating possible implications and applications for making early 
and differential diagnoses, assessing prognosis, monitoring response 
to treatment, and for developing novel anti-cancer strategies.
Introduction
Heat shock proteins (Hsp) constitute a heterogeneous group of 
molecules with a variety of functions, many of which pertain to the 
response to stress and to protein folding. Historically, Hsps were 
considered stress proteins, with a subset of which being typically 
involved in assisting the correct folding of nascent polypeptides and 
in the refolding of partially denatured proteins resulting from cellular 
stress.1-3 These Hsps are the so called molecular chaperones. Very 
often the names Hsp and molecular chaperone are used interchange-
ably, although there are Hsps that have no known chaperoning 
function and, conversely, there are chaperones that do not belong to 
the Hsp group (these are proteins from genes that are not stress genes, 
i.e., they are not inducible by heat or any other known stressor).
Lately, the range of functions attributed to Hsp has greatly 
expanded to encompass participation in protein translocation, 
protein degradation, dissolution of pathologic protein aggregates, 
regulation of gene expression, cell differentiation, DNA replication, 
signal transduction, programmed cell death, cellular senescence and 
carcinogenesis. In addition, the concept of chaperonopathy was 
developed to indicate pathologic conditions due to quantitatively or 
qualitatively defective chaperones.4,5 Furthermore, the use of chaper-
ones in therapeutics, i.e., chaperonotherapy, for a variety of diseases 
is being investigated in many laboratories.6,7
A field currently very active is the study of the role of Hsps in 
carcinogenesis, and of the possible applications of Hsp detection and 
quantification in tissues and biological fluids for cancer diagnosis 
and, by extension, for assessing prognosis and monitoring disease 
progression and for developing antitumor therapeutic tools based 
on Hsps.8-10
Hsp60 is a molecular chaperone known to assist protein folding 
in prokaryotes and in eukaryotic cell organelles. The Hsp60 in the 
latter organelles is evolutionarily related to that present in bacteria, 
and is considered to have originated in the ancestors of some of 
today’s extant species. Its role and applications in human cancer 
development and management are currently actively investigated 
and the results are very encouraging. Hsp60 seems to have potential 
in the areas of diagnosis-prognosis, and prevention and treatment 
of various human cancers. A brief review of representative findings 
made in the last several years is presented here to inform pathologists 
and clinicians and to stimulate basic and clinical research pertaining 
to Hsp60 and cancer. The data available suggest that Hsp60-based 
methods and reagents have potential to become valuable tools for 
practical application in oncopathology.
Intracellular Hsp60
In eukaryotes, Hsp60 typically resides in the organelles mito-
chondria (chaperonin 60 or Cpn60) and chloroplasts (in plants), 
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Hsp60 in human tumors
and interacts with Hsp10 (or Cpn10) while chaperoning nascent 
polypeptides as they progress to achieve a functional conforma-
tion or native status.11-13 Hsp60 also interacts with mitochondrial 
Hsp70 (mortalin),14-16 and with survivin and p53 as it participates 
in the process of apoptosis.17 The levels of mitochondrial Hsp60 are 
regulated via complex mechanisms, one of which involves a DNA-
dependent protein kinase, a molecule that plays a protective role 
against drug-induced apoptosis.18
In addition to its recognized role in protein folding, Hsp60 
has been implicated in intracellular protein trafficking,16,19 and 
in peptide-hormone signalling in an experimental model of Lyme 
neuropathy.20 Hsp60 can bind and interfere with the functions of 
various endogenous and exogenous proteins. For instance, Hsp60 
binds epolactaene, a microbial metabolite that if not bound to the 
chaperone arrests cell cycle and induces the outgrowth of neurites in 
human neuroblastoma cells.21
For many years Hsp60 was considered a typical intraorganellar 
chaperone. However, lately evidence has accumulated to show that 
Hsp60 is also found in the cytosol not only after mitochondrial 
release but also independently of such release, and the evidence 
also indicate that both, the mitochondrial and the cytosolic forms 
of Hsp60 can function in pro-survival or pro-apoptotic pathways, 
depending on the cellular situation.22
Surface Hsp60
Hsp60 can also be found on the surface of normal23 and tumor 
cells.24-26 Increased amounts of Hsp60 on the cell’s surface was 
considered to serve as a danger signal for the immune system leading 
to the activation and maturation of dendritic cells and the generation 
of a antitumor T-cell response.25,27
Quite interestingly from the oncological viewpoint, surface 
Hsp60 has been found associated with alpha-3-beta-1 integrin, a 
protein involved in the adhesion of metastatic breast cancer cells to 
lymph nodes and osteoblasts, with the association being inhibited by 
mizoribine, an Hsp60-binding drug.28 It has also been shown that 
surface Hsp60 plays a critical part in the metastatization of pancreatic 
carcinoma,24 and that presence of Hsp60 on the surface of oral tumor 
cells determines cell lysis induced by gamma-deltaT lymphocytes.29
Extracellular Hsp60
In addition to its intracellular and pericellular locations, Hsp60 
also occurs in the extracellular space and in circulation, a fact that 
has become firmly established only in the last few years, although the 
mechanisms involved in its secretion, exosomal and/or other are not 
yet understood.30,31
Extracellular Hsp60 can interact with a number of cell-surface 
receptors such as CD14, CD40 and Toll-like-receptors (TLRs),32 
can cause pro- and anti-inflammatory effects,33,34 and can bind to 
peptides (e.g., tumor-derived peptide antigens) and present them to 
immune system cells.35 When acting as a pro-inflammatory agent, 
Hsp60 induces secretion of cytokines from professional antigen-
presenting cells and causes activation of T cells.27,36 Hsp60 can also 
stimulate the maturation of dendritic cells via the TLR-2 and -4 
signal-transduction pathways,35 synergizing the pro-inflammatory 
action of IFNgamma.37
Other reported effects of extracellular Hsp60 are induction of 
the release of TNFalpha, the production of nitric oxide, and the 
induction of expression of the Th1-promoting cytokines IL-12 and 
IL-15 in macrophages.37 However, it has to be noticed that some-
times pro-immune effects in experimental models might result from 
Chlamydial-Hsp60 tissue contamination.38
On the other hand, as anti-inflammatory agent, extracellular 
Hsp60 can be a ligand for gamma-delta T lymphocytes in oral 
tumors, determining antitumoral immunosuppression.39,40 After 
stimulation by Hsp60, gamma-deltaT cells showed downregula-
tion of Fas expression and nitric oxide production, leading to a loss 
of mitochondrial membrane potential and caspase-9 activation, 
followed by induction of lymphocyte-cell death.40
Extracellular Hsp60 can also enter into the blood stream and be 
found in plasma of healthy subjects. In one study on 860 healthy 
members of the British Civil Service (457 men and 304 women), 
Hsp60 plasma levels, assessed by ELISA, were below 1 ng/mL in 
46.9% of the subjects tested, between 1 and 1,000 ng/mL in 26.5%, 
and above 1,000 ng/mL in 26.6%. Molecular analyses showed that 
the circulating Hsp60 was the full-length protein lacking the mito-
chondrial import peptide, which suggested that the circulating Hsp60 
originated in the mitochondria of cells that were not identified.41
In another study, it was found that high Hsp60 blood titres are 
correlated with low socioeconomic status, social isolation and, in 
women, psychologic distress.42 However, the significance of Hsp60 
in circulation with regard to tumors was not investigated.
Hsp60 and Tumor Growth
Hsp60 favours the survival of certain types of tumor cells, and 
in some cases it may even be essential for tumor-cell growth. The 
need for Hsp60 by tumor cells has been revealed by various types 
of data. For example, elevated levels of this protein in tumor cells 
have been linked to: (i) ability to survive apoptotic stimuli; (ii) loss 
of replicative senescence; (iii) uncontrolled proliferation; and (iv) 
neoplastic transformation.17,43-45 In addition, it has been shown in 
in vitro experiments that Hsp60 knockdown arrests osteosarcoma 
cell growth.15 Likewise, inhibition of Hsp60 expression by short 
hairpin RNA plasmids stopped tumor cell growth.14
Tumor immunogenicity may also depend on whether tumor cells 
express and secrete Hsp60 or not.46 This observation alerts us to the 
potential predictive usefulness of monitoring levels of Hsp60 in cells 
and biological fluids in order to assess the probability that an effective 
immune response against a tumor will be elicited.
It is well established for some malignancies, both in vitro and 
in vivo, that Hsp60 is cytoprotective for tumor cells by increasing 
the apoptotic threshold.17 It is also known that Hsp60 can enhance 
caspase activation47,48 or conversely, stimulate anti-apoptotic mecha-
nisms involving sequestration of Bax-containing complexes.49 Thus, 
Hsp60 can have opposite effects with regard to tumor cell survival. 
Consequently, Hsp60 may be defined as “the molecular Proteus” of 
tumor cell survival.44
In has been shown in an in vitro model, that Hsp60 expression 
in breast cancer cells is decreased by collagen V, a component of 
normal human breast stroma that is over-deposited in ductal infil-
trating carcinoma.50 Interestingly, collagen V induced apoptosis of 
tumor cells, but the mechanism responsible for it and for the Hsp60 
decrease has not yet been clarified. These are topics that deserve 
investigation to elucidate to what extent, if any, collagenogenesis 
affects tumor progression in vivo and whether a decrease in Hsp60 
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favors tumor cell death or the contrary in breast ductal infiltrating 
carcinoma.
Hsp60 in Human Tumor Specimens: Diagnostic and Prognostic 
Implications
A variety of tumors from a range of tissues have been examined 
to look for the presence and levels of Hsp60, and the results indicate 
that detection and quantification of this Hsp can provide useful 
information for establishing histopathological diagnosis and assess 
prognosis. A compendium of results is displayed in Tables 1 and 2, 
and some are discussed below, tissue by tissue.
Tumors of the nervous system. Hsp60 was shown by RT-PCR to 
be overexpressed in astroglioma cells.51 In contrast, in another study, 
using proteomics, it was found that the levels of Hsp60 are low in 
multiform glioblastomas as compared to the levels in non-tumor 
tissues.52 It was proposed that a better characterization of Hsp60 
involvement in tumor of the nervous system could be useful for 
differential diagnosis and for predicting response to therapy.
Hematolymphopoietic tumors. Hsp60 is widely distributed in 
hematolymphopoietic tissues. Its expression in bone marrow has 
been found to correlate with B-cell maturation,53 but not with matu-
ration of the myeloid and megakaryocytoid lineages.54 Thus, Hsp60 
determination in bone barrow would offer a means of distinguishing 
cell lineages in bone marrow specimens.
Hsp60 levels were investigated in acute lymphoblastic leukaemia 
but no noteworthy changes were observed.53 By contrast, in blasts 
of acute myeloid leukaemia (AML), Hsp60 levels were found 
augmented and correlated with increased levels of CD14, CD15, 
CD33 and CD34, and associated with a poor prognosis in those 
patients carrying unfavorable karyotypes.55
Hsp60 was found increased in malignant circulating cells of 
patients with AML compared with those from chronic myeloid 
leukaemia (CML) patients and with normal peripheral-blood mono-
nuclear cells.56 Thus, assessing levels of Hsp60 in circulating blasts 
has potential as a means for distinguishing blasts of AML from blasts 
of CML.
Hsp60 was found, by immunohistochemical and Western blot-
ting analyses, abundant in Hodgkin’s lymphomas and scarce in 
small lymphocytic lymphomas, anaplastic large cell lymphomas and 
immunoblastic lymphomas.57 These findings suggest that deter-
mination of Hsp60 levels could aid in the differential diagnosis of 
malignant lymphopathies.
Airway tumors. Hsp60, as demonstrated by immunohistochem-
istry and Western blotting, becomes undetectable during bronchial 
carcinogenesis in smokers with chronic obstructive pulmonary 
disease.58,59 Hsp60 was present in normal and hyperplastic bron-
chial epithelium but, in comparison, its levels were low in squamous 
metaplasia, and it was undetectable in dysplasia and adenocarcinoma 
specimens.59 Interestingly, Hsp60 was also undetectable in normal 
epithelium in proximity of cancerous tissue.58 The data reported 
indicate that distinct Hsp60 levels associated with cell-tissue type 
could be distinctive markers of tissue-lesion type and stage in the 
respiratory tract.
Oral tumors. No differences in Hsp60 levels were found between 
normal odontogenic epithelium and ameloblastomas.60 It would, 
therefore, appear that examining tissue levels of Hsp60 provides no 
help in distinguishing normal from malignant dental tissues.
Hsp60 has been found to be involved in inflammatory processes 
that take place during proliferation of the oral lining epithelium, 
leading to progression of periapical inflammatory lesions.61 In 
contrast, Hsp60 expression was not found to be associated with 
carcinogenetic steps in a retrospective immunohistochemical study 
of the dysplasia-carcinoma sequence of oral mucosa.62 Therefore, 
measuring Hsp60 expression levels in oral tissues would have no 
diagnostic value with regard to oral cancer. The same conclusion was 
derived from measurements of Hsp60 levels by ELISA in patients’ 
sera for diagnostic screening of pre-neoplastic oral lesions.63
A different outlook was provided by other studies. Hsp60 
was assessed immunohistochemically in the basal and suprabasal 
epithelium of the oral mucosa and its levels were found signifi-
cantly higher in oral liken planus than in oral fibromas.64 Hsp60 
was absent in squamous cell carcinomas of the tongue, while it 
was present in normal epithelium and present but discontinu-
ously in dysplastic lesions, suggesting that production of the Hsp 
decreased (due to gene downregulation and/or other mechanisms 
accompanying tumorigenesis) progressively with the progression 
of carcinogenesis.65 These data show that low Hsp60 ought to be 
considered a warning sign in evaluating tongue lesions since low 
levels of this protein could indicate that malignant transformation 
is in progress.
Oesophageal tumors. High levels of Hsp60 were observed in 
oesophageal squamous cell carcinomas and were considered to be 
indicators of good prognosis.66 Hsp60 was found elevated in tumor 
tissue compared to normal mucosa, and the high levels of this Hsp 
correlated with an increment of the apoptotic index and with a better 
five-year survival rate.
Gastric tumors. Hsp60 is a major target antigen for the immune 
system in mucosa-associated lymphoid tissue (MALT) lympho-
mas.67 In these lymphomas, Hsp60 has often been found, using 
immunohistochemistry, in follicular dendritic cells.68 The Hsp60 
of Helicobacter pylori (HP) is very similar to human Hsp60 and the 
immune response induced by these two crossreactive molecules has 
been implicated in the development of gastric MALT lymphoma 
(MALToma).67,69 HP-Hsp60 induced IL-8 secretion in gastric 
epithelial cells.70 Moreover, the levels of IgG anti-HP-Hsp60 were 
significantly elevated and correlated with IgG anti-HP levels in 
patients with MALTomas.71 It has also been found that measuring 
the levels of pre-treatment serum IgG antibodies against HP-Hsp60 
in patients with gastric MALToma helped in predicting the regres-
sion, or lack thereof, of the tumors after HP eradication.72
Large bowel tumors. Hsp60 is elevated during colorectal carcino-
genesis and tumor progression, as shown by immunohistochemistry 
(Fig. 1A) and western blotting,73,74 and by cDNA microarray 
analysis.75 The data suggest that immunohistochemistry helps to 
distinguish normal from dysplastic glands in tubular adenomas,73 
while Western blotting can only distinguish colonic polyps from 
normal tissue.76 Hsp60 levels have also been correlated with tumor 
grade and stage74,75 and with occurrence of lymph node metastases 
(Fig. 1B).74 The higher was the level of Hsp60 in tumor specimens, 
the more advanced were the grade and the stage of the tumors. 
Metastatic lymph nodes showed a higher percentage of cells positive 
for Hsp60 in the secondary follicles than the hyperplastic lymph 
nodes. A recent study showed that tissue Hsp60, detected by immu-
nohistochemistry, and anti-Hsp60 antibody titres in serum measured 
by ELISA were significantly higher in patients with colorectal cancers 
compared to controls.77
Hsp60 in human tumors
Tumors of the liver and pancreas. Hsp60 levels were assessed 
by proteomics and found increased in specimens of hepatocellular 
carcinomas (HCCs) from patients with hepatitis C virus (HCV) 
infection, compared with non-cancerous HCV-infected liver tissue.78 
In contrast, Hsp60 levels determined by immunohistochemistry and 
dot immunobloting were not increased in specimens of hepatitis 
B virus (HBV) infected patients with HCCs, compared with non-
tumoral HBV-infected liver tissues.79 These two reports show once 
again that the method used for assessing Hsp60 should be taken into 
consideration in evaluating the results of measuring the levels of this 
Hsp; one method can show increase while another may not. This 
kind of results also indicate that method selection could be critical in 
designing strategies for studying malignant pathological conditions 
in which Hsp60 levels might be altered.
Hsp60 has been found by proteomics to occur in normal exocrine 
parenchyma and ductal adenocarcinomas of pancreas but no correlation 
was observed between Hsp60 levels and tumor differentiation grade.80
Urinary tract tumors. Hsp60 has been found, by immunohis-
tochemistry, in tumor specimens at low levels or absent in patients 
with vesical transitional-cell carcinomas.81,82 Hsp60 levels were 
correlated with outcome, the lower Hsp60 levels the worse was the 
outcome after local treatment of superficial bladder carcinomas.81 
Another research group showed in invasive or high-risk superficial 
bladder cancers that high levels of Hsp60, as detected by immunohis-
tochemistry prior to neoadjuvant chemoradiotherapy, predict a good 
response to treatment.83 In vesical carcinosarcomas, reduced levels of 
Hsp60 were found by immunohistochemistry in comparison with 
those in normal bladder mucosa.84 The data suggest that measuring 
Hsp60 levels have potential in the histopathologic identification of 
bladder carcinosarcomas particularly at early stages.
Tumors of the male reproductive system. Increased levels of 
Hsp60 is an early sign of prostatic carcinogenesis as demonstrated 
by immunohistochemistry in low- and high-grade prostatic intraepi-
thelial lesions, as well as in prostatic adenocarcinomas (Fig. 1C).85 
Table 1  Tumors in which the levels of Hsp60 have been studied providing information directly pertinent to the  
diagnosis
System Tumor Methodsa Hsp60 levels Ref.
Nervous Astroglyoma RT-PCR Elevated 51
 Glioblastoma Proteomics Decreased 52
Haemolympho-poietic Acute lymphoblastic leukaemia 2D-gel electrophoresis No changes 53
 Acute myeloid leukaemia Flow cytometry Elevated 55, 56
 Chronic myeloid leukaemia Flow cytometry No changes 56
 Hodgkin’s lymphoma IHC, WB Elevated 57
 Small lymphocytic lymphoma IHC, WB No changes 57
 Anaplastic large cell lymphoma IHC, WB No changes 57
 Immunoblastic lymphoma IHC, WB No changes 57
Respiratory Bronchial adenocarcinoma IHC, WB Decreased 58, 59
Digestive Ameloblastoma IHC No changes 60
 Oral carcinoma IHC, ELISA No changes 62, 63
 Oral liken planus IHC Elevated 64
 Fibromas IHC No changes 64
 Tongue carcinoma IHC Decreased 65
 Oesophageal squamous carcinoma IHC Elevated 67
 Gastric MALToma IHC Elevatedb 68,69
 Large bowel IHC, WB, cDNA microarray, ELISA Elevated 73–75, 77
 HCV-hepatocellular carcinoma Proteomics  Elevated  78
 HBV-hepatocellular carcinoma IHC, dot-immunoblot No changes 79
 Pancreatic ductal adenocarcinoma Proteomics  No changes 80
Urinary Vesical transitional cell carcinoma IHC Decreased  81,82
 Carcinosarcoma  IHC Decreased  84
Male reproductive Prostate adenocarcinoma IHC Elevated  85, 86
Female reproductive Exocervical carcinoma IHC, WB Elevated 89, 90
 Ovarian carcinoma IHC Elevated 88,89
 Breast ductal invasive carcinoma 2D-gel electrophoresis Elevated  94
Endocrine Adrenal cushing tumor IHC Elevated 97
Skeletal Osteosarcoma IHC, ELISA Elevated or no changes 99–101
 Condroma IHC No changes 102
 Condrosarcoma IHC No changes 102
aAbbreviations: RT-PCR, real time PCR; IHC, immunohistochemistry; WB, Western blotting; Ref., reference. bBoth, human- and Helicobacter pylori Hsp60 are elevated.
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Hsp60 was scarce or absent in normal prostatic 
tissue.85,86 High levels of Hsp60 did not corre-
late with an elevated Gleason’s differentiation 
grade, indicating that determination of Hsp60 
levels would not help in assessing the prognosis 
of prostatic cancer.86
The expression of the hsp60 gene was found 
elevated in prostatic carcinoma cell lines derived 
from human tumors compared to normal 
human prostatic epithelial cells.87 Interestingly, 
hsp60 expression did not change significantly 
after heat shock, indicating that carcinogenesis 
was the primum movens of the gene’s expres-
sion. The data indicate that determination of 
Hsp60 levels can help in the histopathological 
identification of malignant prostatic cells. In 
what regards prognosis assessment of prostatic 
cancer, available data are less encouraging as 
discussed in the first paragraph of this subsec-
tion, and because no consistent correlation 
was found between levels of Hsp60 in tumor 
specimens and outcome of primary prostatic 
cancers.86,88
Tumors of the female reproductive system. 
Hsp60 was found elevated, as measured by 
immunohistochemistry and Western blotting, 
in pre-neoplastic and neoplastic lesions of the 
cervix.89,90 The levels of Hsp60 increased from 
low-grade squamous intraepithelial lesions 
(SIL) through high-grade SIL to invasive carci-
nomas.90
Exposure to chronic persistent Chlamydia 
trachomatis (CT) infection has been associated 
with the development of ovarian and cervical 
cancers.91 It was hypothesized that CT-Hsp60 
Table 2  Examples of tumors in which the levels of Hsp60 have been studied providing information useful in  
predicting prognosis
Tumor Hsp60 levels Correlation with patients’ outcome Ref.a
Acute myeloid leukaemia Elevated Worse prognosis in patients with unfavourable phenotype 55
Oral carcinoma No changes Scarce utility 63
Oesophageal squamous Elevated  Elevated correlates with a better five-year survival 64 
carcinoma
Gastric MALToma Elevated Helicobacter pylori (HP) Hsp60 elevated predicts tumor 72 
  regression after HP eradication
Vesical transitional cell Decreased Lower levels correlate with worse outcome of local treatments 81 
carcinoma
  Higher levels prior to neoadjuvant chemoradiotherapy correlate 83 
  with better treatment response
Prostate adenocarcinoma Elevated No correlation between Hsp60 levels and outcome 87
Ovarian carcinoma Elevated Higher levels correlate with worse prognosis in patients treated 92 
  with cisplatin-containing chemotherapy
  Higher levels correlate with earlier stage and better outcome 93
Osteosarcoma Elevated (or not) No correlation with outcome 100, 101
aRef., reference.
Figure 1. Immunohistochemical detection of Hsp60 provides useful insights for histopathologi-
cal diagnosis of primary and metastatic tumors. Some illustrative examples are shown here. (A) 
Colorectal adenocarcinoma (CRAC) is typically positive for Hsp60 (most clearly seen on top and 
toward the right-hand upper quadrant of the picture). In contrast, normal colonic glands are negative 
for Hsp60 (arrow). (B) Hsp60 immunostaining helps to identify CRAC Hsp60-positive metastatic cells 
in a lymph node. (C) Hsp60-positive primary adenocarcinoma cells detected in a needle biopsy 
specimen taken from a prostatic nodule. The same patient had bone-marrow metastases, which were 
also Hsp60 positive (D).
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exerts an antiapoptotic effect on tumoral cells by inhibiting caspase-3 
activation, polyADP-ribose polymerase hydrolysis, and mitochon-
drial cytochrome-c release.91 Since CT produces considerable 
quantities of Hsp60, determination of CT-Hsp60 could become a 
tool useful in the diagnosis (and possibly in assessing the prognosis) 
of ovarian and cervical cancers.
In ovarian carcinomas, it was shown by immunohistochem-
istry that high levels of Hsp60 predicted poor survival in patients 
undergoing chemotherapy that included cisplatin, since Hsp60 
mediates drug resistance.92 In another study, it was shown by immu-
nohistochemistry that occurrence of Hsp60 was more frequent in 
epithelial ovarian carcinomas at the initial stage in patients that later 
showed a better outcome than in patients that did not do well.93 
Thus, in epithelial ovarian carcinomas, high levels of Hsp60 in the 
early stages seem to predict a good prognosis.
Breast tumors. Hsp60 has been found elevated by two dimen-
sional gel electrophoresis in ductal carcinomas as compared to 
normal breast tissues.94 In contrast, no correlation was found 
between levels of Hsp60 (as determined by immunohistochemistry) 
and tumor size, and between levels of Hsp60 and hormone receptor 
and HER-2 status.95 Similarly, no correlation was observed between 
Hsp60 levels (determined by microarray analysis) and tumor stage 
or presence of metastases in regional lymph nodes in breast carcino-
mas.96 In summary, the potential of determining levels of Hsp60 in 
the diagnosis and in assessing the prognosis of breast tumors varies 
depending on the method used and on tumor type.
Tumors of the endocrine system. Only one study has come to our 
attention on Hsp60 in tumors of the endocrine system. The study 
showed increased Hsp60 levels as determined by immunohistochem-
istry in adrenal Cushing tumors.97 Thus, it should be explored 
further whether determination of Hsp60 in the adrenal is a reliable 
accessory tool for diagnosing Cushing tumors.
Skin and soft tissue tumors. Hsp60 has been investigated in 
skin tumors (e.g., melanoma) and in malignancies originating in 
mesenchimal cells (e.g., osteosarcoma and chondrosarcoma). For 
example, Hsp60 was found increased by proteomics and real-time 
PCR in cultured cells isolated from metastatic malignant melanomas 
as compared with cells isolated from primary melanomas.98 Thus 
this determination deserves testing as a way to distinguish metastatic 
from primary melanomas.
In osteosarcomas, anti-Hsp60 antibodies were found elevated in 
the patients’ sera at the time of first diagnosis,99 and Hsp60 was also 
elevated in tumor specimens as measured by immunohistochemis-
try.100 In contrast, a previous comparative study of osteosarcomas 
and non-malignant bone tumors did show significant differences in 
Hsp60 levels between the two types of specimens as measured by 
immunhistochemistry.101 Therefore, more research is necessary to 
establish whether or not determination of Hsp60 levels in osteosar-
comas has potential as a diagnostic/prognostic indicator, but the data 
available at the present time are encouraging.
The situation with cartilage tumors is still unclear. No significant 
differences in Hsp60 levels (as detected by immunohistochemistry) 
were observed between chondromas and chondrosarcomas;102 thus 
Hsp60 determinations do not seem to offer a promising tool to 
distinguish these two tumors from one another.
Hsp60 as Anti-tumor Agent and as Target for Anti-Hsp60 
Compounds that Would Inhibit its Pro-Tumoral Activity
Hsp60, endogenous and overexpressed therapeutically or exoge-
nous and administered as gene or as protein, has potential in anticancer 
therapy via various mechanisms.36 Examples of these anti-tumor 
mechanisms actively involving Hsp60 are: (i) arrest of intracel-
lular pro-survival (e.g., anti-apoptotic) pathways; (ii) stimulation 
of pro-apoptotic mechanisms; (iii) induction of Hsp60 surface 
expression and/or release into the extracellular space with activation 
of an antitumor immune response.
Since some Hsps are known to enhance tumor growth, the 
development of anti-Hsp agents for use in cancer therapy is under 
investigation. For instance, various classes of Hsp90 inhibitors 
have been developed in the last few years, and some of them are 
showing promising results in preclinical and clinical studies.103-105 
Similar efforts have not, to our knowledge, been made to develop 
anti-Hsp60 compounds, although these efforts seem justified at the 
present time, considering the new information available on Hsp60 
functions and role in carcinogenesis discussed in this article.
The levels of Hsp60 can be manipulated with therapeutic 
purposes in various ways. Flavonoids can lower the levels of Hsp60 
in a number of human tumor cell lines,106 whereas cadmium induces 
hsp60 gene expression in hepatoma cell lines.107 In vitro experiments 
have shown in a variety of tumor cells that photodynamic therapy 
(FDT) can induce hsp60-gene upregulation,108,109 as well as Hsp60 
surface localization.110 hsp60-gene upregulation might be respon-
sible for the tumor-cell resistance to various forms of anti-cancer 
agents observed after FDT.108 Intratumoral inoculation of immature 
dendritic cells after FDT, in in vivo experiments, resulted in an effec-
tive antitumor immune response evidenced by stimulation of the 
cytotoxic activity of T and NK cells.109
hsp60-gene silencing by small interfering RNA (siRNA) in breast 
and colon adenocarcinoma cells induced mitochondrial dysfunction, 
Hsp60-p53 complex disruption, Bax overexpression and Bax- (or 
caspase-) dependent apoptosis.17 In contrast, siRNA-silencing of 
Hsp60 in normal cells did not elicit apoptosis. Thus, it would appear 
that knocking down or disabling Hsp60 would promote apoptosis in 
cancer cells only, which would make this treatment a specific killer of 
malignant cells, at least in breast and colon cancers.
The data summarized in the preceding paragraphs of this section 
are indicative of a definite potential of Hsp60 as anti-tumor agent, 
and as the basis of anticancer strategies aiming to promote tumor cell 
destruction with preservation of normal cell counterparts.
Hsp60 may also have a role as adjuvant for vaccines. DNA 
vaccines encoding Hsp60 linked to HPV16 E6 and E7 for human 
papillomaviruses-associated cervical cancer show a more potent 
immunotherapeutic effect than the tumor antigen without the 
Hsp.111 Caution is in order though, since Hsp60 tolerance can be 
induced by repeated Hsp60 administration, which also induces cross-
tolerance to other pro-inflammatory stimuli, thus potentially limiting 
the possible applications of this Hsp as an adjuvant or enhancer of 
the immune response against tumors or other pathogenic agents.112
In an experimental model, Hsp60-containing exosomes derived 
from heat-shocked mouse B-lymphoma cells induced a substantial 
antitumor CD8(+) T cell response.30 The data suggest that exosome-
based vaccines with Hsp60 deserve further exploration as candidates 
for the development of novel antitumor strategies.
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Since treatment of malignant tumors usually involves chemo-
therapy, the impact of the latter on Hsp60 levels and functions has 
been investigated. For example, proteomic analysis revealed that 
doxorubicin does not cause significant alteration of Hsp60 levels in 
human breast cancer cells.113 Contrarily, Hsp60 levels were notably 
increased after exposure of human ovarian114 and cervix squa-
mous115 cancer cells to cisplatin. Since Hsp60 has a pro-survival role 
in these tumor cells, it could play a key role in the development of 
the intrinsic tumor cell resistance to anti-cancer agents induced by 
cisplatin.
Concluding Remarks
Even though much has been done regarding Hsp60 roles in 
tumor cell survival and growth and in other cellular mechanisms, 
and some research has been performed concerning the use of this 
Hsp for oncologic diagnosis and therapy, still much more needs to 
be done. For instance, the presence or absence of Hsp60 in a variety 
of tumors has not yet been investigated so, for these tumors, it is 
impossible to decide whether determinations of Hsp60 will be useful 
for diagnostic or therapeutic purposes. Expression of the hsp60 gene 
and levels of Hsp60 in relation to tumor progression and diseases 
prognosis have also not yet been determined for many important 
tumors. Furthermore, in those tumors already studied, most of the 
data come from immunohistochemical observations, sometimes 
complemented with Western blotting or proteomics, but informa-
tion at the gene transcription and regulation levels is scarce. Similarly, 
detailed biochemical analyses of the molecular mechanisms involving 
Hsp60 that pertain to apoptosis and other related intracellular events 
relevant to tumor-cell growth and migration are limited. Likewise, 
the role of extracellular Hsp60 in tumor progression and in deter-
mining patient’s prognosis remains for the most part to be elucidated. 
Further studies need to be conducted to establish the value of circu-
lating Hsp60 as a cancer biomarker with clinical utility.
While it is true that a lot remains to be done for establishing the 
uses of Hsp60 determinations in oncology, the data available at this 
time are encouraging. It has become clear that assessing the levels 
of Hsp60 could be helpful in surgical pathology for a number of 
neoplasms, as discussed in this article. Briefs comments on some of 
the promising results follow.
Demonstration of Hsp60 in tumors of the digestive tract helped 
to: (i) distinguish dysplastic from normal tissue in tubular adenomas 
of the large bowel; (ii) demonstrate lymph node metastasis in 
colorectal adenocarcinoma; and (iii) detect vascular and neural 
malignant invasion.
In an illustrative case pertaining to the male reproductive tract, 
a bone marrow metastasis from a prostatic adenocarcinoma showed 
high levels of Hsp60 mimicking those of the primary tumor (Fig. 
1D, unpublished data from the authors). In regard to the female 
reproductive tract, demonstration of Hsp60 helped to assess SIL 
level of exocervical dysplasia. Demonstration of low levels of Hsp60 
aided in the diagnosis of bronchial, lingual and vesical carcinomas, 
and glioblastomas.
Another potential application of Hsp60 determinations would be 
in assessing prognosis and in monitoring the response to treatment. 
On these two areas, few studies have been reported but encour-
aging information has been gathered pertaining to AML, gastric 
MALToma and oesophageal and vesical carcinomas and, to a lesser 
extent, ovarian cancer.
Future goals should be to: (i) elucidate molecular mechanisms that 
cause up or downregulation of the hsp60 gene during carcinogenesis; 
(ii) elucidate and explain mechanistically at the molecular level 
the effects of Hsp60 on tumor cell growth and viability, including 
elucidation of the Hsp60 interactions with other molecules such as 
those of apoptotic pathways; (iii) determine when and why during 
tumorigenesis Hsp60 appears on the outside of the cell membrane 
and/or is released into the extracellular space; (iv) use transgenic mice 
overexpressing Hsp60 to determine whether the incidence of cancer 
increases, decreases or remains unchanged, depending on the tumor 
type for example; (v) apply Hsp60 knockouts or knockdowns tech-
niques to attempt to modulate tumor growth in vivo; (vi) establish 
when in the course of the disease modifications of Hsp60 levels in 
tumor specimens do become good diagnostic indicators; (vii) estab-
lish if, and when during the disease process, Hsp60 becomes a serum 
marker useful for cancer diagnosis and/or for following up disease 
progression and response to treatment; and (viii) use the information 
pertaining to the preceding seven points to design new diagnostic/
prognostic methods and antitumor therapies based on Hsp60 gene 
or protein.
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